Tab Amiodarone

# Tab amiodarone ## Overview - **Classification**: Class III antiarrhythmic agent. - **Mechanism**: Prolongs cardiac action potential and refractory period, primarily by blocking potassium channels. Also has alpha/beta blocking, calcium channel blocking, and sodium channel blocking properties. ## Primary Indications 1. **Ventricular Arrhythmias**: Treatment and prophylaxis of recurrent ventricular fibrillation (VF) and hemodynamically unstable ventricular tachycardia (VT). 2. **Supraventricular Arrhythmias**: Rate control and rhythm conversion in atrial fibrillation (AFib) or atrial flutter (AFlutter), especially with structural heart disease or refractory to other agents. ## Adult Dosing ### Standard Dosing **Life-threatening Ventricular Arrhythmias (e.g., recurrent VF/unstable VT)** - **Loading Dose**: **800-1600 mg/day**. - **Frequency**: Once daily or divided **BID**. - **Route**: Oral. - **Duration**: **1-3 weeks** or until initial therapeutic response. - **Maintenance Dose**: **400 mg/day**. - **Frequency**: Once daily. **Supraventricular Arrhythmias (e.g., AFib)** - **Loading Dose**: **600-800 mg/day**. - **Frequency**: Once daily or divided **BID**. - **Route**: Oral. - **Duration**: **1-2 weeks**. - **Maintenance Dose**: **100-400 mg/day**. - **Frequency**: Once daily. - **Special Considerations**: Use the lowest effective dose. ### Dose Adjustments - **Renal Impairment**: No specific dose adjustment is generally needed. Monitor for adverse effects. - **Hepatic Impairment**: Use with caution. Consider lower starting doses and slower titration. Monitor LFTs closely; avoid in severe hepatic dysfunction. - **Elderly Patients**: May be more susceptible to adverse effects. Start with lower doses and titrate slowly. Monitor thyroid, pulmonary, and liver function. ## Pediatric Dosing *(Note: Oral amiodarone use in pediatrics is often off-label, complex, and requires close monitoring.)* ### Neonates (0-28 days) - **Indication**: Refractory supraventricular or ventricular arrhythmias. - **Dose**: **10-15 mg/kg/day** (loading), then **5-10 mg/kg/day** (maintenance). - **Frequency**: Once daily or divided **BID**. - **Maximum**: **15 mg/kg/day** (loading), **300 mg/day** (overall). - **Special Notes**: Highly variable pharmacokinetics. Requires close ECG and plasma level monitoring. Oral solutions (compounded) are often used. ### Infants (1-12 months) - **Indication**: Refractory supraventricular or ventricular arrhythmias. - **Dose**: **10-15 mg/kg/day** (loading) for **7-10 days**. - **Frequency**: Once daily or divided **BID**. - **Maximum**: **300 mg/day** during loading. - **Maintenance**: **5-10 mg/kg/day**, adjusted to response. - **Special Notes**: Monitor for thyroid, liver, and pulmonary toxicity. Use lowest effective dose. ### Children (1-12 years) - **Indication**: Refractory supraventricular or ventricular arrhythmias. - **Dose**: **10-15 mg/kg/day** (loading) for **7-10 days**. - **Frequency**: Once daily or divided **BID**. - **Maximum**: **300 mg/day** during loading. - **Maintenance**: **5-10 mg/kg/day**, adjusted to response. - **Maximum Maintenance**: **400 mg/day**. - **Special Notes**: Monitor thyroid, liver, and pulmonary function, and ECG. ### Adolescents (13-18 years) - **Dose**: Generally follows adult dosing guidelines. - **Loading Dose**: **800-1600 mg/day** for **1-3 weeks**. - **Maintenance Dose**: **100-400 mg/day**. - **Maximum**: **1600 mg/day** for loading, **400 mg/day** for maintenance. - **Special Notes**: Consider pubertal development when applying adult dosing. ## Safety Information ### Contraindications - **Absolute**: Severe sinus node dysfunction (e.g., sinus bradycardia, SA block) without a functional pacemaker. - **Absolute**: Second or third-degree AV block without a functional pacemaker. - **Absolute**: Hypersensitivity to amiodarone or iodine. - **Absolute**: Cardiogenic shock. ### Common Adverse Effects - **Very Common (>10%)**: Corneal microdeposits (usually asymptomatic), GI upset (nausea, vomiting, constipation), photosensitivity. - **Common (1-10%)**: Thyroid dysfunction (hypo/hyperthyroidism), liver enzyme elevation, peripheral neuropathy, tremor, dizziness, fatigue, skin discoloration (blue-gray). - **Serious but Rare**: Pulmonary fibrosis, severe hepatotoxicity, exacerbation of arrhythmia (proarrhythmia), optic neuropathy/neuritis, Torsades de Pointes. ### Key Drug Interactions - **Warfarin**: **Increased INR/bleeding risk**. Reduce warfarin dose by **30-50%** when starting amiodarone. Monitor INR closely. - **Digoxin**: **Increased digoxin levels**. Reduce digoxin dose by **50%**. Monitor digoxin levels. - **Statins (Simvastatin, Lovastatin)**: **Increased statin levels/rhabdomyolysis risk**. Limit simvastatin to **20 mg/day** or use alternative statin (e.g., rosuvastatin, pravastatin). - **QT-prolonging drugs**: **Increased risk of Torsades de Pointes**. Avoid co-administration if possible (e.g., fluoroquinolones, macrolides, TCAs, some antipsychotics). - **CYP3A4 inhibitors (e.g., grapefruit juice, azole antifungals, macrolides)**: **Increased amiodarone levels**. Monitor for toxicity. - **CYP3A4 inducers (e.g., rifampin, St. John's wort)**: **Decreased amiodarone levels**. May reduce efficacy. ## Monitoring & Follow-up - **Before Treatment**: Baseline ECG, chest X-ray, pulmonary function tests (PFTs), thyroid function tests (TSH, free T4), liver function tests (ALT, AST), electrolytes (K+, Mg2+). - **During Treatment**: - **LFTs & TSH**: Every **3-6 months** or as clinically indicated. - **ECG**: Periodically to assess rhythm control and QTc interval. - **Ophthalmologic exam**: Annually or if visual changes occur. - **Pulmonary assessment**: If symptoms (dyspnea, cough) arise; consider chest X-ray/PFTs. - **Clinical Signs**: Watch for dyspnea, dry cough, jaundice, unexplained fatigue, vision changes, new bradycardia, or signs of worsening arrhythmia. ## Clinical Pearls - 💡 **Long Half-Life**: Amiodarone has an extremely long half-life (**up to 58 days**). Effects and side effects can persist for months after discontinuation. - 💡 **Oral Absorption**: Highly variable. Take with food to improve absorption and reduce GI upset. - 💡 **Photosensitivity**: Counsel patients to use sunscreen and protective clothing. Blue-gray skin discoloration can occur with long-term use. - 💡 **Prophylactic Pacing**: Essential if patient has pre-existing bradyarrhythmias or conduction blocks before initiation. - 💡 **Pill Burden**: The high loading doses can be challenging for adherence. Counsel patients on the importance of consistent dosing. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.